CALYPTE BIOMEDICAL CORPORATION
2,282,434 SHARES OF COMMON STOCK
You should read this prospectus supplement and the related prospectus
carefully before you invest. Both documents contain information you should
consider when making your investment decision.
On September 4, 2002, we issued a draw down notice to Townsbury
Investments Limited ("TIL") in connection with the common stock purchase
agreement dated August 23, 2001 evidencing a standby equity-based credit
facility between us and TIL. This notice required that TIL purchase up to
$250,000 of our common stock pursuant to a pricing formula in the stock purchase
agreement. The settlement period began on September 5, 2002, ended on September
11, 2002, and settled on September 17, 2002. At the final settlement date on
September 17, 2002, TIL purchased a total of 2,282,434 shares of our common
stock at an average purchase price of $0.110 per share, resulting in proceeds of
$237,000 net of brokerage fees. Ladenburg Thalmann & Co. received $12,500 in
brokerage fees and the escrow agent received $500 in escrow fees in connection
with this drawdown.
The attached prospectus relates to the resale of shares acquired by TIL
pursuant to the stock purchase agreement. Because TIL may sell some or all of
these shares, and because there are currently no agreements, arrangements or
understandings with respect to the sale of any of these shares, we cannot
estimate the actual amount of shares that they will hold after the completion of
the offering.
We will not receive any of the proceeds from this sale of shares by
TIL. However, we did receive the sale price of common stock sold to TIL. We
expect to use the proceeds of this sale of common stock for general corporate
purposes.
This Prospectus Supplement is incorporated by reference into the
Prospectus, and all terms used herein shall have the meaning assigned to them in
the Prospectus. See "Risk Factors" beginning on page 4 of the accompanying
prospectus and on page 37 of our annual report on Form 10-K/A for the year ended
December 31, 2001, which is being delivered to you with the accompanying
prospectus, for a description of certain factors that should be considered by
prospective Investors.
These securities have not been approved or disapproved by the
Securities and Exchange Commission or any state securities commission nor has
the Securities and Exchange Commission or any state securities commission passed
upon the accuracy or adequacy of this prospectus. Any representation to the
contrary is a criminal offense.
The date of this Prospectus Supplement is September 17, 2002.
|
Thread abonnieren
ETF-Sparplan